

Causal inference for infectious disease intervention in inter-connected clusters

Xiaoxuan Cai

joint work with Eben Kenah, Forrest W. Crawford

Department of Biostatistics, Mailman School of Public Health
Columbia University


March 16, 2021

ENAR 2021


Infectious disease and vaccination

Distinct mechanisms of infectious disease interventions/vaccinations,

- Direct protection for the treated individuals:
 - direct effect, vaccine efficacy, susceptibility effect...
- Indirect protection for the surrounding individuals:
 - indirect effect, herd immunity, contagion effect, infectiousness effect...
- Vaccines for Polio, Influenza, HIV/AIDS, Malaria and etc.



Direct protection



Indirect protection

Why infectious disease is difficult to study?

Research on transmission of infectious disease has some unique features and challenges.

- The infection outcome of one individual also depends on others' treatments, conditional on other individuals being infected.
– **Interference**
- The outcome of interest (infection) is transmissible, so outcomes are not independent from each other. – **Contagion**
- The infection times of others compose an important factor for the infection outcome – **Exposure to infection**
Earlier exposure to infectious individual (higher "exposure to infection") increases the risk of infection.

One infection outcome depends on (i) its **own treatment**, (ii) **treatments of others**, and (iii) **infection times of others**.

Bias due to differential “exposure to infection”

Direct comparisons of treated and untreated individuals may not be valid due to differential “exposure to infection” [1,2,3].

$$E[Y_i|X_i = 1] - E[Y_i|X_i = 0]$$

- For example, if vaccinated individuals get infected later in general, then later infected and vaccinated subjects face higher exposure to infection, comparing to earlier infected and unvaccinated individuals.
→ not a fair comparison !

Can randomization solve the problem?

- No. Differential “exposure to infection” due to others’ infection happens after randomization.


[1] Longini et al. Statistical inference for infectious diseases: risk-specific household and community transmission parameters. *American Journal of Epidemiology*, 128(4):845–859, 1988.

[2] Halloran et al. Direct and indirect effects in vaccine efficacy and effectiveness. *American Journal of Epidemiology*, 133(4):323–331, 1991.

[3] Halloran et al. Exposure efficacy and change in contact rates in evaluating prophylactic HIV vaccines in the field. *Statistics in Medicine*, 13(4):357–377, 1994.

Challenges for causal identification

Consider a interconnected four individuals with treatment (X_1, X_2, X_3, X_4) and infection outcome (Y_1, Y_2, Y_3, Y_4).



- The graph is not an acyclic directed graph (DAG).

Propose new methodology to evaluate interventions effects for contagious outcomes

We will provide new methods that

- Do not depend on certain study design or randomization strategy
- Apply to various transmission dynamics, cluster size and observational time
- Incorporate individual- and cluster-level covariates
- Yield biologically meaningful causal estimands for direct and indirect protection provided by interventions
- Allow flexible statistical inferential framework, ranging from parametric, semi-parametric to non-parametric estimation

Notation

Consider a cluster of n individuals, $i = 1, \dots, n$, denote

- Treatment assignment: $\mathbf{X} = (X_1, \dots, X_n)$
- Infection time: $\mathbf{T} = (T_1, \dots, T_n)$
- Infection outcome: $\mathbf{Y}(t) = (Y_1(t), \dots, Y_n(t))$,
where $Y_i(t) = \mathbb{1}\{T_i < t\}$

For a focal subject i , denote

- Others' treatments: $\mathbf{X}_{(i)} = (X_1, \dots, X_{i-1}, X_{i+1}, \dots, X_n)$
- Others' infection times: $\mathbf{T}_{(i)} = (T_1, \dots, T_{i-1}, T_{i+1}, \dots, T_n)$
- Others' infection history: $\mathcal{H}_{(i)}(t) = \{Y_j(s) : 0 \leq s < t, j \neq i\}$,
or equivalently, $\mathcal{H}_{(i)}(t) = \{T_j; T_j < t, j \neq i\}$

Note: $\mathcal{H}_{(i)} = \{Y_j(s) : s \geq 0, j \neq i\}$, or equivalently, $\mathcal{H}_{(i)} = \mathbf{T}_{(i)}$

Notation

Define $T_i(\mathbf{X} = \mathbf{x}, \mathcal{H}_{(i)} = \mathbf{h}_{(i)})$ and $Y_i(t; \mathbf{X} = \mathbf{x}, \mathcal{H}_{(i)} = \mathbf{h}_{(i)})$ as the counterfactual infection time and outcome of i under a joint treatment \mathbf{x} and a deterministic infection history $\mathbf{h}_{(i)}$ of other individuals, respectively.

Goal 1

Identify $T_i(\mathbf{x}, \mathbf{h}_{(i)})$ or $Y_i(t; \mathbf{x}, \mathbf{h}_{(i)})$ under joint intervention $(\mathbf{x}, \mathbf{h}_{(i)})$.

- (i) own treatment: $X_i = x_i$
- (ii) others' treatments: $\mathbf{X}_{(i)} = \mathbf{x}_{(i)}$
- (iii) others' infection times: $\mathbf{h}_{(i)}$

Main Result: Exposure-controlled potential outcome

Goal 1

Identify $T_i(\mathbf{x}, \mathbf{h}_{(i)})$ or $Y_i(t; \mathbf{x}, \mathbf{h}_{(i)})$ under joint intervention $(\mathbf{x}, \mathbf{h}_{(i)})$.

Theorem: Identification of exposure-controlled potential outcomes

Under conventional assumptions in causal inference,

$$\mathbb{E}[Y_i(t; \mathbf{h}_{(i)}, \mathbf{x}) \mid \mathbf{L} = \mathbf{l}] = \sum_{j=0}^{n-1} \left[F_{I_i^j}(\min\{t, t_{(i)}^{j+1}\} - t_{(i)}^j \mid \mathbf{x}, \mathbf{h}_{(i)}, \mathbf{l}) \prod_{k=0}^{j-1} (1 - F_{I_i^k}(t_{(i)}^{k+1} - t_{(i)}^k \mid \mathbf{x}, \mathbf{h}_{(i)}, \mathbf{l})) \right]$$

where $F_{I_i^j}(s \mid \mathbf{x}, \mathbf{h}_{(i)}, \mathbf{l})$ –distribution of $I_i^k(\mathbf{x}, \mathbf{h}_{(i)})$ – is identifiable by standard results from competing risks.

Main Result: Exposure-marginalized potential outcomes

- $\mathcal{H}_{(i)}^*(\mathbf{x})$: the random history of infection times in individuals other than i under $\mathbf{X} = \mathbf{x}$, in an otherwise identical group of $n - 1$ individuals in which i is absent, or cannot transmit infection.

Goal 2

Identify $Y_i(t; \mathbf{x}, \mathcal{H}_{(i)}^*(\mathbf{x}_{(i)}))$ under joint intervention \mathbf{x} and $\mathcal{H}_{(i)}^*(\mathbf{x}_{(i)})$.

Theorem: Identification of exposure-marginalized potential outcomes


Under conventional assumptions in causal inference,

$$\mathbb{E}[Y_i(t; \mathbf{x}_i, \mathbf{x}_{(i)}, \mathcal{H}_{(i)}^*(\mathbf{x}'_{(i)})) | \mathbf{L} = \mathbf{l}] = \int \mathbb{E}[Y_i(t; \mathbf{x}_i, \mathbf{x}_{(i)}, \mathbf{h}_{(i)}) | \mathbf{L} = \mathbf{l}] dG_{(i)}^*(\mathbf{h}_{(i)} | \mathbf{x}'_{(i)}, \mathbf{l}_{(i)})$$


where $\mathbf{x}'_{(i)}$ may (not) equal to $\mathbf{x}_{(i)}$, and $G_{(i)}^*(\mathbf{h}_{(i)} | \mathbf{x}_{(i)}, \mathbf{l}_{(i)})$ – the distribution of $\mathcal{H}_{(i)}^*(\mathbf{x}_{(i)})$ – is identified by standard results from competing risks.

Simulation: causal identification for potential outcomes

We simulate $N=100,000$ clusters of **three** individuals with constant exogenous and internal infection hazards, without covariates.



Controlled-exposure outcome



Marginalized-exposure outcome

Causal estimands: Exposure-marginalized causal estimands

Exposure-marginalized (natural) causal estimands

- Susceptibility effect

$$SE_i(t, \mathbf{x}_{(i)}) = \mathbb{E}[Y_i(t; \mathbf{1}, \mathbf{x}_{(i)}, \mathcal{H}_{(i)}^*(\mathbf{x}_{(i)})) - Y_i(t; \mathbf{0}, \mathbf{x}_{(i)}, \mathcal{H}_{(i)}^*(\mathbf{x}_{(i)}))]$$

- Infectiousness effect

$$IE_i(t, x_i, \mathbf{x}_{(i)}) = \mathbb{E}[Y_i(t; x_i, \mathbf{1}, \mathcal{H}_{(i)}(\mathbf{x}_{(i)})) - Y_i(t; x_i, \mathbf{0}, \mathcal{H}_{(i)}(\mathbf{x}_{(i)}))]$$

- Contagion effect

$$CE_i(t, x_i, \mathbf{x}_{(i)}, \mathbf{x}'_{(i)}) = \mathbb{E}[Y_i(t; x_i, \mathbf{x}_{(i)}, \mathcal{H}_{(i)}^*(\mathbf{x}_{(i)})) - Y_i(t; x_i, \mathbf{x}_{(i)}, \mathcal{H}_{(i)}^*(\mathbf{x}'_{(i)}))]$$

- Susceptibility effect → shows if the vaccine protects treated individual
- Infectiousness effect → shows if the vaccine decreases transmission ability
- Contagion effect → shows if the disease is contagious

Traditional estimands on the cluster level

- Direct effect:

$$DE(t) = \mathbb{E}[Y_i(t)|X_i = 1] - \mathbb{E}[Y_i(t)|X_i = 0]$$

- Indirect effect:


$$\begin{aligned} IDE(t) &= \sum_{|\mathbf{x}_{(i)}|=\frac{n}{2}} \mathbb{E}[Y_i(t)|X_i = 0, \mathbf{X}_{(i)} = \mathbf{x}_{(i)}]p(\mathbf{x}_{(i)}) \\ &\quad - \sum_{|\mathbf{x}_{(i)}|=0} \mathbb{E}[Y_i(t)|X_i = 0, \mathbf{X}_{(i)} = \mathbf{x}_{(i)}]p(\mathbf{x}_{(i)}) \end{aligned}$$

Simulation: Estimations of causal estimands


Cluster	Treatment	Probability estimands				
		$\hat{C}E(t, 0, \mathbf{0}, \mathbf{1})$	$\hat{S}E(t, \mathbf{0})$	$\hat{I}E(t, \mathbf{0}, \mathbf{0})$	$DE(t)$	$IDE(t)$
Constant external and internal hazards						
2	Obs.	0.005	-0.015	-0.036	-0.013	-0.036
	Bernoulli	0.004	-0.015	-0.036	-0.014	-0.038
	Block	-	-	-	0.025	-
	Cluster	-	-	-	-0.048	-
4	Obs.	0.026	-0.014	-0.084	-0.012	-0.073
	Bernoulli	0.025	-0.013	-0.082	-0.012	-0.063
	Block	-	-	-	0.016	-
	Cluster	-	-	-	-0.099	-
8	Obs.	0.068	-0.013	-0.131	-0.010	-0.088
	Bernoulli	0.069	-0.014	-0.133	-0.010	-0.096
	Block	-	-	-	0.010	-
	Cluster	-	-	-	-0.154	-

Simulation under $e^{\beta_1} = 0.9$, $e^{\beta_2} = 0.1$, $\alpha(t) = 0.3$, $\gamma(t) = 3$ and $e^{\theta_1} = e^{\theta_2} = 0.9$. Clusters of 2, 4, and 8 are observed at 0.4, 0.3 and 0.2 year.

Biased $DE(t)$ over time under different cluster sizes



How do epidemiologists understand infectious disease transmission?



Cox-type hazard model for pairwise infection times

Assume previously infected individuals, along with a exogenous source of infection, impose **independent** and **competing** risks of disease transmission to the remaining uninfected individuals. For all i and all infected individual j , $j \neq i$, we consider a Cox-type hazard model for:

- **External** source of infection:

$$\lambda_{0i}(t | x_i, \mathbf{l}_i) = \alpha(t) \exp[\beta_1 x_i + \theta_1^T \mathbf{l}_i]$$

- **Internal** source of infection from infectious j to yet-uninfected i :

$$\lambda_{ji}(t | x_i, \mathbf{l}_i) = \gamma(t - t_j) \exp[\beta_1 x_i + \beta_2 x_j + \theta_1^T \mathbf{l}_i + \theta_2^T \mathbf{l}_j]$$

$\beta_1 < 0$ means a beneficial treatment effect on treated individuals.

$\beta_2 < 0$ means a decreased transmission risk due to vaccination.

$\gamma(t) > 0$ means an infectious disease.

Simulation: Estimations of causal estimands

Cluster	Treatment	Hazard estimands		Probability estimands				
		$\hat{\beta}_1$	$\hat{\beta}_2$	\hat{CE}	\hat{SE}	\hat{IE}	$DE(t)$	$IDE(t)$
Constant external and internal hazards								
2	Obs.	-0.119	-2.271	0.005	-0.015	-0.036	-0.013	-0.036
	Bernoulli	-0.115	-2.334	0.004	-0.015	-0.036	-0.014	-0.038
	Block	-0.102	-2.364	0.004	-0.013	-0.036	0.025	-
	Cluster	-0.103	-2.288	0.004	-0.013	-0.035	-0.048	-
4	Obs.	-0.105	-2.368	0.026	-0.014	-0.084	-0.012	-0.073
	Bernoulli	-0.105	-2.286	0.025	-0.013	-0.082	-0.012	-0.063
	Block	-0.116	-2.278	0.026	-0.015	-0.082	0.016	-
	Cluster.	-0.107	-2.323	0.025	-0.014	-0.083	-0.099	-
8	Obs.	-0.100	-2.287	0.068	-0.013	-0.131	-0.010	-0.088
	Bernoulli	-0.106	-2.331	0.069	-0.014	-0.133	-0.010	-0.096
	Block	-0.111	-2.311	0.069	-0.014	-0.132	0.010	-
	Cluster	-0.120	-2.299	0.070	-0.016	-0.132	-0.154	-

Simulation under $e^{\beta_1} = 0.9$, $e^{\beta_2} = 0.1$, $\alpha(t) = 0.3$, $\gamma(t) = 3$ and $e^{\theta_1} = e^{\theta_2} = 0.9$. Clusters of 2, 4, and 8 are observed at 0.4, 0.3 and 0.2 year.

Summary

- We articulate the causal structure between individuals' treatments and outcomes in infectious disease, and illustrate the identification strategy for the potential outcomes under contagion, in the example of inter-connected clusters.
- A class of fundamental (controlled- and marginalized-) causal estimands for the susceptibility, infectiousness and contagion effect of vaccines are proposed, and comprehensively compared to popular estimands in contemporary epidemiology.
- We provide the identification of causal estimands non-parametrically, and further apply a generalized Cox-type transmission hazard model to facilitate the inference of causal estimands.
- We promote hazard ratio as alternative causal estimands for the susceptibility and infectiousness effect, and compared them to existing estimands for vaccine efficacy.

Acknowledgement

This work was supported by National Institutes of Health (NIH) grant NICHD/BD2K 1DP2HD09179 and R01 AI116770. Xiaoxuan Cai was supported by a fellowship from Takeda Pharmaceutical Company. We thank Peter Aronow, Olga Morozova, Virginia Pitzer for their great suggestions.

xc2577@cumc.columbia.edu
<https://xiaoxuan-cai.github.io/>